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The corticosteroidogenicity of ACTH-derived peptides was tested in a purified isolated rat adrenal cell 
system. The activity was related to the activity of standard ACTH (synthetic hACTHlm3’; potency fixed 
at 100). The peptides ACTHI’-“NH2 and ACTHI’-” showed steroidogenicity at pharmacological doses 
(potencies: 0.00067 and 0.00032, respectively). None of the peptides tested inhibited or potentiated the 
ACTH-induced steroidogenesis at low doses (0.5-50 000 pg). The results suggest he presence of a second 
center within the ACTH molecule capable of inducing steroidogenesis. 
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1. INTRODUCTION 
According to the current concept, 4 functional 
sites in the ACTH molecule can be identified: (i) 
the center of ACTH concerning the corticosteroid 
production which has been localized in the 5-10 
amino acid sequence of the molecule [l]; (ii) the 
basic amino acids in the sequence 15-18 and in 
position 11 which play a pivotal role in the binding 
and affinity of the molecule to the receptor [2,3]; 
(iii) the sequence l-3 which potentiates the 
steroidogenic effect [4]; (iv) the acid amino acids 
localized within the sequence 25-32 which protect 
the vulnerable amino acid sequence 15-18 against 
tryptic-like degradation [5,6]. 
ACTH11-19NH2 alone and in the presence of 
hACTH1-39. We did not find an inhibitory effect 
in physiological doses, but with pharmacological 
doses we found a steroidogenic effect with these 
fragments indicating the existence of a second 
steroidogenic center in ACTH. 
2. MATERIALS AND METHODS 
In accordance with its binding function it has 
been demonstrated that the sequence 1 l-24 in- 
hibits the complete molecule [7]. As in this latter 
study a large overdose of ACTH”-” had to be 
added for the inhibition of the steroidogenesis of 
the complete ACTH molecule in a crude isolated 
adrenal cell preparation, we studied in our purified 
adrenal cell system the effects of ACTH”-” and 
Synthetic hACTH1-39 (revised sequence [S]) 
with a potency of 188 IU/mg as estimated in [9] 
was used as standard. This standard, ACTH7-13 
NH2 and ACTH11-24 were generous gifts from Dr 
W. Rittel and Dr P. Dessaulles (CIBA-Geigy Ltd, 
Basle). Another ACTH11-24 preparation was kind- 
ly supplied by Dr H. Greven (Organon, 0s~). 
ACTH11-19NH2 was generously provided by Dr 
M. Nakamura (Shionogi & Co., Osaka) and 
ACTHlm4 and ACTH5-’ by Dr K. Medzihradszky. 
In the bioassay isolated rat adrenal cells were 
used which were purified and pre-incubated before 
ACTH addition. This methodology has been ex- 
tensively described [6]. Potencies of the ACTH 
Published by Elsevier Science Publishers B. V. 
00145793/84/$3.00  1984 Federation of European Biochemical Societies 23 
Volume 173, number 1 FEBS LETTERS 
Table 1 
Potencies of ACTH-derived peptides 
Peptide Potency SD n Highest dose 
tested (ug) 
hACTH1-39 100 
ACTH’-4 nda 3 100 
ACTH’-’ nd 3 100 
ACTH7-13NH2 nd 5 100 
ACTH”-24 0.00032 0.00011 10 
ACTH”-%Hz 0.00067b 0.00025 5 
a nd, not detectable 
b Statistically significant difference between this value and the value 
of ACTHi’-” (P < 0.01) 
peptides were analyzed as follows. For each pep- 
tide complete log dose-response curves were con- 
structed. The potencies of the peptides were ex- 
pressed as the relation of the reciprocal of their 
molar ED50 to the reciprocal of the molar EDso of 
the standard. Human ACTH1-39 was assigned to 
the potency of 100 
July 1984 
Differences between means were statistically 
tested using the Mann-Whitney two sample rank 
test. 
3. RESULTS 
The steroidogenic potencies of the peptides are 
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Fig.1. Log dose-response curves for ACTH peptides without the 5-10 amino 
means of duplicate estimations. 
24 
acid sequence. Symbols represent the 
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Fig.2. The effect of different doses of ACTH’1-‘9NH2 (O”“‘O), ACTH”-24 (D---O) and ACTH7-13 NH2 (A---A) 
upon the steroidogenesis induced by 25 pg hACTH’-39. 
shown in table 1. The peptides ACTHle4, 
ACTHse7 and ACTH7-13NHz evoked no steroido- 
genie response, not even in doses as high as 100 pg. 
The peptides ACTH”-24 and ACTH”-i9NH~ did 
show an albeit low but still measurable biological 
activity. The potency of ACTH”-‘%IHz was 
observed to be, statistically, significantly higher 
than the potency of ACTH”-” (P < 0.01). No 
statistically significant difference was found bet- 
ween the potencies of the ACTH1’-24 peptides ob- 
tained from different sources (Organon, 0.00035 f
0.00012; n = 6; CIBA-Geigy, 0.00027 f 0.00008; 
n = 4). The log dose-response curves of both 
ACTH”-24 and ACTH’*-‘9NH~ were parallel to 
the curve of the standard (fig.1). 
In three experiments the influence of 
ACTHi’-“, ACTH ‘l-lgNH~ and ACTH7-13NHz 
- in doses without steroidogenic activity - upon 
the ACTH-induced steroidogenesis was studied. 
Fig.2 shows that none of these peptides inhibited 
or potentiated the activity of ACTH in the doses 
tested. 
4. DISCUSSION 
Our finding that the peptides ACTHlF4, 
ACTH’-’ and ACTH7-13NHr elicited no cor- 
ticosterone production (table 1) is in agreement 
with the concept that a compIete amino acid se- 
quence S-10 is responsible for steroid production 
[I]. However, in contradiction with this concept 
and with other reports we found an, albeit low, but 
still measurable steroidogenic activity of the mid- 
portion peptides ACTH”-24 and ACTH1r-‘gNH~ 
with a potency comparable to that of ACTH’-‘* 
[6]. In isolated adrenal cells authors in [7] found 
that ACTH’ 1-24 - in a pharmacological dose - 
was able to inhibit the steroidogenic activity of 
human ACTHlm3’, whereas this peptide did not 
reveai steroidogenic activity by itself. Remarkably, 
the author in [lo] employing ACTH”-“NH2 
observed a potentiating effect of the ACTH- 
induced steroidogenesis n vitro as well as in vivo, 
whereas the peptide itself did not show any 
steroidogenicity. In this respect, it is noteworthy 
that authors in [ll] did find formation of CAMP 
induced by ACTH’*-” in a huge dose of 100 pg - 
in the presence of the GTP analogue Gpp(NH), - 
in a rat adrenal adenylate cyclase system. In our 
cell suspensions lower doses up to 50 ng 
ACTH”-” and ACTHi”-‘%Hz showed neither 
inhibition nor potentiation of ACTH (fig.2). These 
results are discrepant from the reports mentioned 
earlier but the reason for this is not clear. Maybe 
25 
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methodological differences in isolation of the 
adrenal cells - we used collagenase whereas the 
other authors employed trypsin which has been 
reported to damage cell receptors in fat cells (121 
- or in the quality of the cell suspension - we 
used purified, preincubated cells, whereas the 
other authors did not purify or preincubate the 
cells - could account for these discrepancies. 
In addition to the results mentioned above it is 
of interest that in other biological systems 
ACTH’ i-24 has been reported to be able to express 
biological activity. In rat adipocytes lipolysis could 
be induced by the 11-24 sequence to about the 
same degree as ACTH’-lo [13]. Moreover, 
ACTH’1-24 contains a message sequence for activi- 
ty in the central nervous system 1141. These results 
together are in favour of the presence of a second 
steroidogenic enter in the ACTH molecule. As is 
known, the sequence 15-18 which contains the 
basic amino acids is responsible for the binding 
and affinity to the receptor f2J and therefore the 
sequence 11-14 may be of some interest in this 
respect. in this context it is remarkable that 
authors in [ 151 found a second bioactive center in 
the molecule for cu-MSH activity, namely the se- 
quence 11-13. 
The finding that ACTH11-19NH~ shows a, 
statistically, significantly higher potency than 
ACTH”-24 points at a role of the amino acid se- 
quence 20-24 for an optimal steroidogenic activity 
of the midportion peptides. This is similar to 
observations made in [16]. These authors found 
about the same magnesium-accumulating activity 
in rat adipocyte plasma membranes both for 
ACTH’-” and ACTH ‘lw2*. Removal of residues 
21-24, however, as in ACTHle2’, resulted in a 
reduction of this activity by almost two-thirds. In 
addition they found a significantly greater hpolytic 
activity for ACTH’-20 than for ACTH’-” in rat 
adipocytes. As the magnesium accumulation men- 
tioned involves the mediation of an a-adrenergic 
receptor [16], it seems worthwhile to further in- 
vestigate the similarity of the findings in [16] and 
ours. The influence of a-adrenergic agonists and 
antagonists on the steroidogenicity of the midpor- 
tion peptides could further elucidate the 
characteristics of the second steroidogenic enter. 
Furthermore, the existence of two separate 
steroidogenic enters in the ACTH molecule, as we 
found here, fits very well with the results of the 
26 
tracer binding study [17], where two different 
types of receptors were found, each with different 
binding constants. These two receptor populations 
have different requirements for stimulating the 
adrenocortical cell [4]. Because of the fact that the 
two types of receptor presumably have different 
effects on the CAMP production [18], it is of in- 
terest to study the nature of the new steroidogenic 
center further by estimating the CAMP production 
in response to the addition of ACTHI’-“. 
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